Citations

Clear

16280 citation(s) found for "Yu, David".

O4‐03‐07: A Comparison of Network Connectivity and Atrophy Patterns in Behavioral Variant Frontotemporal Dementia
Whitwell, Jennifer L. , Avula, Ramesh, Gunter, Jeffrey L. , Petersen, Ronald C. , Jones, David T. , Zeng, Guang‐Zhi , Vemuri, Prashanthi , McDade, Eric , Machulda, Mary M. , Knopman, David S. , Boeve, Bradley F. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 26, 2010 | Volume: 6 | Issue: 4S_Part_20 | Pages: No page available

10.1016/j.jalz.2010.08.052 Get It

Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan
Kost, James, Assaid, Christopher, Lines, Christopher, Ho, Tony W. , Dodick, David W.

Mayo Clinic

Cephalalgia | October 11, 2010 | Volume: 31 | Issue: 3 | Pages: 296-300

10.1177/0333102410385585 | PMID 20937606 Get It

Background: Endpoints used to evaluate the efficacy of acute anti-migraine drugs do not measure the tolerability. Sustained pain-free response with no adverse events has been recommended as a composite endpoint which measures the efficacy and tolerability attributes that patients desire. Methods: The aim of this study was to evaluate new composite efficacy-plus-tolerability endpoints based on a post-hoc analysis of patient-level data from a previous randomized, placebo-controlled trial of the calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, and zolmitriptan in the acute treatment of migraine. Endpoints were 2–24-hour sustained pain freedom and no adverse events from 0–24 hours (SPF24NAE), 2–24 hour sustained pain relief and no adverse events from 0–24 hours (SPR24NAE), pain freedom at 2 hours and no adverse events from 0–24 hours (PF2NAE), and pain relief at 2 hours and no adverse events from 0–24 hours (PR2NAE). Results: Compared with placebo, both telcagepant 300 mg and 150 mg achieved nominal superiority ( p values <.05) for SPF24NAE, SPR24NAE, PF2NAE and PR2NAE. Zolmitriptan 5 mg showed nominal superiority versus placebo for SPF24NAE, SPR24NAE and PF2NAE, but not PR2NAE. Telcagepant 300 mg showed nominal superiority versus zolmitriptan for SPF24NAE, SPR24NA and PR2NAE. Conclusion: Composite efficacy-plus-tolerability endpoints may be useful for facilitating comparisons between treatments.
REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer
Comins, Charles, Spicer, James , Protheroe, Andrew , Roulstone, Victoria , Twigger, Katie, White, Christine , Vile, Richard G. , Melcher, Alan , Mettinger, K.L., Nuovo, Gerard J., Cohn, David E. , Phelps, Mitch A. , Harrington, Kevin J. , Pandha, Hardev , Coffey, Matt C. , Melcher, Alan A , Harrington, Kevin , Cohn, David , Phelps, Mitch

Mayo Clinic

Clinical Cancer Research | October 7, 2010 | Volume: 16 | Issue: 22 | Pages: 5564-5572

10.1158/1078-0432.ccr-10-1233 | PMID 20926400 Get It

Abstract Purpose: REOLYSIN (Oncolytics Biotech) consists of a wild-type oncolytic reovirus, which has selective cytotoxicity for tumor cells while sparing normal cells. In a phase I study as a single agent, repeated infusions of reovirus were safe with evidence of antitumor activity. Preclinical studies indicate potential for synergy between reovirus and chemotherapeutic agents. A multicenter, phase I dose escalation study was designed to assess the safety of combining reovirus with docetaxel chemotherapy in patients with advanced cancer. Experimental Design: Patients received 75 mg/m2 docetaxel (day 1) and escalating doses of reovirus up to 3 × 1010 TCID50 (days 1-5) every 3 weeks. Results: Twenty-five patients were enrolled, and 24 patients were exposed to treatment, with 23 completing at least one cycle and 16 suitable for response assessment. Dose-limiting toxicity of grade 4 neutropenia was seen in one patient, but the maximum tolerated dose was not reached. Antitumor activity was seen with one complete response and three partial responses. A disease control rate (combined complete response, partial response, and stable disease) of 88% was observed. Immunohistochemical analysis of reovirus protein expression was observed in posttreatment tumor biopsies from three patients. Conclusion: The combination of reovirus and docetaxel is safe, with evidence of objective disease response, and warrants further evaluation in a phase II study at a recommended schedule of docetaxel (75 mg/m2, three times weekly) and reovirus (3 × 1010 TCID50, days 1-5, every 3 weeks). Clin Cancer Res; 16(22); 5564–72. ©2010 AACR.
Development and Validation of Risk Adjustment Models for Long-Term Mortality and Myocardial Infarction Following Percutaneous Coronary Interventions
Holmes, David R. , Lennon, Ryan J. , Rihal, Charanjit S. , Singh, Mandeep , Rihal, Charanjit S.

Mayo Clinic

Circulation: Cardiovascular Interventions | October 6, 2010 | Volume: 3 | Issue: 5 | Pages: 423-430

10.1161/circinterventions.109.924308 | PMID 20923988 Get It

Background— Existing models for outcome after percutaneous coronary interventions (PCIs) lack assessment of long-term prognosis. Our goal was to derive 1- and 5-year mortality and mortality/myocardial infarction (MI) risk models for PCI outcomes from simple, easily obtainable clinical and laboratory variables. Methods and Results— Using the Mayo Clinic registry, we analyzed long-term mortality and mortality/MI following PCIs on 9165 unique patients from January 1, 2001, through December 31, 2007. Cox proportional hazards regression was used to model the calculated risk score and major procedural complications. A total of 1243 patients died, and 696 had MI. Separate risk models derived from clinical, procedural, and laboratory characteristics were made for mortality and mortality/MI. Older age, comorbid conditions, low ejection fraction, acute MI, history of smoking, heart failure, hyperlipidemia, 3-vessel disease, procedural failure, ventricular arrhythmia during PCI, and low medication score were predictors of long-term mortality and mortality/MI. Simple integer scores stratified patients into low, moderate, high, and very high risk for subsequent events. Models had adequate goodness of fit, and areas under the receiver operating characteristic curve were 0.786 and 0.728 for mortality and mortality/MI, respectively, indicating good overall discrimination. Bootstrap analysis indicated that the model was not overfit to the available data set. Conclusions— Easily obtainable variables can be combined into a convenient risk scoring system at the time of patient dismissal following PCI to accurately predict long-term mortality and mortality/MI. This model may be useful for providing patients with individualized, evidence-based estimates of long-term risk.
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Hoff, Daniel D. Von , Stephenson, Joseph J., Rosen, Peter J., Loesch, David, Anthony, Stephen P. , Jameson, Gayle , Brown, Susan B., Cantafio, Nina, Richards, Donald , Fitch, Tom R., Wasserman, Ernesto, Green, Sylvan, Sutherland, William, Bittner, Michael , Alarcon, Arlet, Mallery, David, Penny, Robert, Borad, Mitesh J. , Fernández, Cristian

Mayo Clinic

Journal of Clinical Oncology | October 4, 2010 | Volume: 28 | Issue: 33 | Pages: 4877-4883

10.1200/jco.2009.26.5983 | PMID 20921468 Get It

Purpose To compare the progression-free survival (PFS) using a treatment regimen selected by molecular profiling (MP) of a patient's tumor with the PFS for the most recent regimen on which the patient had experienced progression (ie, patient as his own control). Patients and Methods Patients with refractory metastatic cancer had tissue samples submitted for MP in two formats including formalin-fixed tissue for immunohistochemistry and fluorescent in situ hybridization assays and immediately frozen tissue for oligonucleotide microarray (MA) gene expression assays (all performed in a Clinical Laboratory Improvement Amendments [ CLIA ] –certified laboratory). The MP approach was deemed of clinical benefit for the individual patient who had a PFS ratio (PFS on MP-selected therapy/PFS on prior therapy) of ≥ 1.3. Results In 86 patients who had MP attempted, there was a molecular target detected in 84 (98%). Sixty-six of the 84 patients were treated according to MP results. Eighteen (27%) of 66 patients had a PFS ratio of ≥ 1.3 (95% CI, 17% to 38%; one-sided, one-sample P = .007). Therefore, the null hypothesis (that ≤ 15% of this patient population would have a PFS ratio of ≥ 1.3) was rejected. Conclusion It is possible to identify molecular targets in patients' tumors from nine different centers across the United States. In 27% of patients, the MP approach resulted in a longer PFS on an MP-suggested regimen than on the regimen on which the patient had just experienced progression. Issues to be considered in interpretation of this study include limited prior experience with patients as their own controls as a study end point and overall patient attrition.
Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma
Sekulić, Aleksandar , Kim, Su Y. , Savage, Stephanie, Einspahr, Janine G., Prasad, Anil , Sagerman, Paul, Curiel‐Lewandrowski, Clara , Bowden, G. Timothy, Warneke, James, Alberts, David S., Pittelkow, Mark R. , DiCaudo, David J. , Nickoloff, Brian J. , Trent, Jeffrey M. , Bittner, Michael , Hostetter, Galen H. , Krouse, Robert S.

Mayo Clinic

Cancer Prevention Research | September 28, 2010 | Volume: 3 | Issue: 10 | Pages: 1277-1283

10.1158/1940-6207.capr-10-0058 | PMID 20876729 Get It

Abstract Cutaneous squamous cell carcinoma (SCC) occurs commonly and can metastasize. Identification of specific molecular aberrations and mechanisms underlying the development and progression of cutaneous SCC may lead to better prognostic and therapeutic approaches and more effective chemoprevention strategies. To identify genetic changes associated with early stages of cutaneous SCC development, we analyzed a series of 40 archived skin tissues ranging from normal skin to invasive SCC. Using high-resolution array-based comparative genomic hybridization, we identified deletions of a region on chromosome 10q harboring the INPP5A gene in 24% of examined SCC tumors. Subsequent validation by immunohistochemistry on an independent sample set of 71 SCC tissues showed reduced INPP5A protein levels in 72% of primary SCC tumors. Decrease in INPP5A protein levels seems to be an early event in SCC development, as it also is observed in 9 of 26 (35%) examined actinic keratoses, the earliest stage in SCC development. Importantly, further reduction of INPP5A levels is seen in a subset of SCC patients as the tumor progresses from primary to metastatic stage. The observed frequency and pattern of loss indicate that INPP5A, a negative regulator of inositol signaling, may play a role in development and progression of cutaneous SCC tumors. Cancer Prev Res; 3(10); 1277–83. ©2010 AACR.
Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors
Schaid, Daniel J. , Goss, Paul E., Liu, Mohan , Chapman, Judy-Anne W., Kubo, Michiaki , Jenkins, Gregory D. , Batzler, Anthony , Shepherd, Lois E. , Pater, Joseph L. , Wang, Liewei , Stearns, Vered , Rohrer, Daniel C. , Pritchard, Kathleen I. , Flockhart, David A., Nakamura, Yusuke , Weinshilboum, Richard M. , Ingle, James N. , Mushiroda, Taisei , Chapman, Judy‐Anne W., Ellis, Matthew J. , Goetz, Matthew P. , Weinshilboum, Richard M. , Stearns, Vered

Mayo Clinic

Journal of Clinical Oncology | September 28, 2010 | Volume: 28 | Issue: 31 | Pages: 4674-4682

10.1200/jco.2010.28.5064 | PMID 20876420 Get It

Purpose We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer. Patients and Methods A nested case-control design was used to select patients enrolled onto the MA.27 phase III trial comparing anastrozole with exemestane. Cases were matched to two controls and were defined as patients with grade 3 or 4 MS-AEs (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0) or those who discontinued treatment for any grade of MS-AE within the first 2 years. Genotyping was performed with the Illumina Human610-Quad BeadChip. Results The GWAS included 293 cases and 585 controls. A total of 551,358 SNPs were analyzed, followed by imputation and fine mapping of a region of interest on chromosome 14. Four SNPs on chromosome 14 had the lowest P values (2.23E-06 to 6.67E-07). T-cell leukemia 1A (TCL1A) was the gene closest (926-7000 bp) to the four SNPs. Functional genomic studies revealed that one of these SNPs (rs11849538) created an estrogen response element and that TCL1A expression was estrogen dependent, was associated with the variant SNP genotypes in estradiol-treated lymphoblastoid cells transfected with estrogen receptor alpha and was directly related to interleukin 17 receptor A (IL17RA) expression. Conclusion This GWAS identified SNPs associated with MS-AEs in women treated with AIs and with a gene (TCL1A) which, in turn, was related to a cytokine (IL17). These findings provide a focus for further research to identify patients at risk for MS-AEs and to explore the mechanisms for these adverse events.
The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Mantese, Vito A., Timaran, Carlos H. , Chiu, David, Begg, Richard J., Brott, Thomas G.

Mayo Clinic

Stroke | September 27, 2010 | Volume: 41 | Issue: 10_suppl_1 | Pages: No page available

10.1161/strokeaha.110.595330 | PMID 20876500 Get It

Background and Purpose— Carotid artery stenosis causes up to 10% of all ischemic strokes. Carotid endarterectomy (CEA) was introduced as a treatment to prevent stroke in the early 1950s. Carotid stenting (CAS) was introduced as a treatment to prevent stroke in 1994. Methods— The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is a randomized trial with blinded end point adjudication. Symptomatic and asymptomatic patients were randomized to CAS or CEA. The primary end point was the composite of any stroke, myocardial infarction, or death during the periprocedural period and ipsilateral stroke thereafter, up to 4 years. Results— There was no significant difference in the rates of the primary end point between CAS and CEA (7.2% versus 6.8%; hazard ratio, 1.11; 95% CI, 0.81 to 1.51; P =0.51). Symptomatic status and sex did not modify the treatment effect, but an interaction with age and treatment was detected ( P =0.02). Outcomes were slightly better after CAS for patients aged <70 years and better after CEA for patients aged >70 years. The periprocedural end point did not differ for CAS and CEA, but there were differences in the components, CAS versus CEA (stroke 4.1% versus 2.3%, P =0.012; and myocardial infarction 1.1% versus 2.3%, P =0.032). Conclusions— In CREST, CAS and CEA had similar short- and longer-term outcomes. During the periprocedural period, there was higher risk of stroke with CAS and higher risk of myocardial infarction with CEA. Clinical Trial Registration— www.clinicaltrials.gov. Unique identifier: NCT00004732.
Smoking and Pain
Shi, Yu , Weingarten, Toby N. , Mantilla, Carlos B. , Hooten, W. Michael , Warner, David O. , Mantilla, Carlos B , Weingarten, Toby N

Mayo Clinic

Anesthesiology | September 24, 2010 | Volume: 113 | Issue: 4 | Pages: 977-992

10.1097/aln.0b013e3181ebdaf9 | PMID 20864835 Get It

Cigarette smoke, which serves as a nicotine delivery vehicle in humans, produces profound changes in physiology. Experimental studies suggest that nicotine has analgesic properties. However, epidemiologic evidence shows that smoking is a risk factor for chronic pain. The complex relationship between smoking and pain not only is of scientific interest, but also has clinical relevance in the practice of anesthesiology and pain medicine. This review will examine current knowledge regarding how acute and chronic exposure to nicotine and cigarette smoke affects acute and chronic painful conditions. It will cover the relevant pharmacology of nicotine and other ligands at the nicotinic acetylcholine receptor as related to pain, explore the association of cigarette smoking with chronic painful conditions and potential mechanisms to explain this association, and examine clinical implications for the care of smokers with pain.
Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
Saper, Joel R., Silberstein, Stephen D., McCarville, Sally, Sun, Mark Y., Goadsby, Peter J. , Dodick, David W. , Goadsby, Peter J

Mayo Clinic

Cephalalgia | September 23, 2010 | Volume: 31 | Issue: 3 | Pages: 271-285

10.1177/0333102410381142 | PMID 20861241 Get It

Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache ≥15 days per month. Methods: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responders were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups. Results: Seventy-five of 110 subjects were assigned to a treatment group; complete diary data were available for 66. A responder was defined as a subject who achieved a 50% or greater reduction in number of headache days per month or a three-point or greater reduction in average overall pain intensity compared with baseline. Three-month responder rates were 39% for AS, 6% for PS and 0% for MM. No unanticipated adverse device events occurred. Lead migration occurred in 12 of 51 (24%) subjects. Conclusion: The results of this feasibility study offer promise and should prompt further controlled studies of ONS in CM.